Nothing said here yet.
to join the conversation.
| Chin Peter ScottChief Medical Officer | Sell | 1,654 | $36.9K | Fri, Sep 4 |
| Thornberry NancyDirector | Sell | 10,824 | $247.3K | Wed, Sep 2 |
| Thornberry NancyDirector | Sell | 615 | $14.6K | Wed, Sep 2 |
| Schuth Alexander O.COFO and Secretary | Sell | 2,768 | $64.9K | Tue, Sep 1 |
Denali Therapeutics has delivered a mixed share price journey, with sharp gains over the past year sitting against a much weaker longer track record.
Denali Therapeutics (DNLI) has pulled back sharply, with the share price down about 15% over the past month and 27% in the past 3 months. This decline has drawn fresh attention to its valuation.
Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.
AVLAYAH revenue hit $3.6M in first full quarter post-approval.
Denali Therapeutics narrows Q2 loss as Avlayah sales top estimates, with strong launch traction and pipeline updates shaping its outlook.
Moby summary of Denali Therapeutics Inc.'s Q2 2026 earnings call
Denali Therapeutics (NASDAQ:DNLI) reported $3.6 million in net product revenue from AVLAYAH during the second quarter of 2026, its first full quarter of commercial availability, as the company expanded payer access and advanced two Alzheimer’s disease programs into clinical development.
Denali Therapeutics (DNLI) delivered earnings and revenue surprises of +5.56% and +143.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Strong first full quarter of AVLAYAH™ (tividenofusp alfa-eknm) launch generated $3.6 million in net product revenueAdvanced TransportVehicle™ portfolio with two Alzheimer’s disease programs now in clinical development$195 million in gross proceeds received in July 2026 from sale of a Priority Review Voucher, bringing pro forma cash, cash equivalents and marketable securities to more than $1.1 billionConference call and webcast today at 4:30 p.m.
SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it will report financial results and business highlights for the second quarter ended June 30, 2026, on Thursday, August 6, 2026.